Jump to content

Ceftobiprole: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
changed chembl id
Line 42: Line 42:
| KEGG = D08885
| KEGG = D08885
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 407727
| ChEMBL = 520642


<!--Chemical data-->
<!--Chemical data-->

Revision as of 12:42, 23 January 2012

Ceftobiprole
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Intravenous
ATC code
Identifiers
  • (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)- 2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)- 3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.129.666 Edit this at Wikidata
Chemical and physical data
FormulaC20H22N8O6S2
Molar mass534.568 g/mol g·mol−1
3D model (JSmol)
  • O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(\N=O)=C2/NSC(\N)=N2)/C=C4\CCN(C4=O)[C@@H]5CCNC5)C(O)=O
  • InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,26H,1-4,6-7H2,(H2,21,24)(H,23,29)(H,32,33)/b8-5+,14-11+/t10-,12-,18-/m1/s1 checkY
  • Key:LXLDMYXULSBRCX-KOGKARRDSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ceftobiprole (Zeftera/Zevtera) is a fifth-generation[2] cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Pseudomonas aeruginosa, and enterococci.[3][4][5] It was discovered by Basilea Pharmaceutica[6] and was developed by Johnson & Johnson Pharmaceutical Research and Development.[7] It has been shown to be statistically noninferior to the combination of vancomycin and ceftazidime for the treatment of skin and soft tissue infections.[citation needed]

It has been described as a fifth-generation cephalosporin,[8][9] though acceptance for this terminology is not universal.

Pharmacology

Ceftobiprole inhibits the 2a penicillin-binding protein (PBP) of methicillin-resistant Staphylococcus aureus and the 2x PBP of Streptococcus pneumoniae,[4] as well as the classic PBP-2 of MSSA. Ceftobiprole is resistant to staphylococcal β-lactamase.[6]

Dosing

Ceftobiprole cannot be given by mouth, so is given intravenously. It is not FDA approved for use in children.[5]

Ceftobiprole has been approved for use in Canada and Switzerland, and is under review by regulatory authorities in the United States, the European Union, Australia, Russia and South Africa.[10] In November 2008, the US FDA declined to approve ceftobiprole, citing data integrity concerns with two of the supporting studies,[11] and prompting Basilea to sue Johnson & Johnson for breach of license agreement on February 2009.[12]

Synonyms

  • RO0639141-000[6]
  • BAL9141[13]
  • Ceftobiprole medocaril

References

  1. ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Retrieved 2008-09-05.
  2. ^ Kollef MH (2009). "New antimicrobial agents for methicillin-resistant Staphylococcus aureus". Crit Care Resusc. 11 (4): 282–6. PMID 20001879. {{cite journal}}: Unknown parameter |month= ignored (help)
  3. ^ Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". Diagnostic Microbiology and Infectious Disease. 59 (4): 463. doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ a b Widmer A (2008). "Ceftobiprole: A new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin Infect Dis. 46 (5): 656–8. doi:10.1086/526528. PMID 18225983.
  5. ^ a b Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS (2008). "A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections". Clin Infect Dis. 46 (5): 647–55. doi:10.1086/526527. PMID 18225981.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ a b c Hebeisen P, Heinze-Krauss I, Angehrn P; et al. (2001). "In vitro and in vivo properties of Ro63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci". Antimicrob Agents Chemother. 45 (3): 825–36. doi:10.1128/AAC.45.3.825-836.2001. PMC 90381. PMID 11181368. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  7. ^ Basilea.com
  8. ^ Widmer AF (2008). "Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus". Clin. Infect. Dis. 46 (5): 656–8. doi:10.1086/526528. PMID 18225983. {{cite journal}}: Unknown parameter |month= ignored (help)
  9. ^ Kosinski MA, Joseph WS (2007). "Update on the treatment of diabetic foot infections". Clin Podiatr Med Surg. 24 (3): 383–96, vii. doi:10.1016/j.cpm.2007.03.009. PMID 17613382. {{cite journal}}: Unknown parameter |month= ignored (help)
  10. ^ Basilea superbug drug approved in Canada, Reuters News, June 30, 2008
  11. ^ http://www.dancewithshadows.com/pillscribe/ceftobiprole-antibiotic-to-fight-tougher-bacterial-infections-fails-to-win-approval-in-us/
  12. ^ "Basilea Pharmaceutica Ltd. announces that the U.S. Food and Drug Administration (FDA) issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (Johnson & Johnson PRD), a Complete Response Letter on ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI" (Press release). Basilea Pharmaceutica. 2009-07-02. Retrieved February 2, 2010.
  13. ^ Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002). "In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci". J Antimicrob Chemother. 50 (6): 915–932. doi:10.1093/jac/dkf249. PMID 12461013.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ceftobiprole&oldid=472791777"